[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgical-blood-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgical-blood-loss":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,76,107,137,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100547904","phase-3-tranexamic-acid-for-reduction-of-transfusion-in-abdominal-surgery-100547904",false,"NCT06414031","Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery","Tranexamic Acid for Reduction of Intra- and Postoperative Transfusion Requirements in Elective Abdominal Surgery: Randomized Controlled Trial","TATRA","Inclusion Criteria:\n\n1. Age 18 years or above\n2. Planned elective esophagectomy, gastrectomy, colectomy, rectal resection, pancreatic resection, or hepatectomy\n3. Adequate renal function with serum creatinine \\\u003C250 µmol\u002FL (2.82 mg\u002FdL)\n4. Written informed consent obtained before randomization\n5. Negative pregnancy test for women of childbearing potential within 14 days of commencing study treatment. Females of reproductive potential must agree to practice highly effective contraceptive measures during the study. These comprise measures with a failure rate of \\\u003C1% per year when used consistently and correctly, such as intravaginal and transdermal combined (oestrogen and progestogen containing) hormonal contraception, injectable and implantable progestogen-only hormonal contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion; vasectomised partner, sexual abstinence (defined as refraining from heterosexual intercourse during the entire study period).\n\nExclusion Criteria:\n\n1. Severe anaemia, defined as a haemoglobin concentration \\\u003C8 g\u002FdL (\\\u003C5 mmol\u002FL) or anaemia with haemoglobin concentration ≥8 to \\\u003C10 g\u002FdL (≥5,0 to \\\u003C6,2 mmol\u002Fl) and one or several of the following symptoms suggesting hypoxemia:\n\n   * Clinical signs of tachycardia, e.g., resting heart rate \\>100 beats\u002Fminute, palpitation etc.\n   * Clinical signs of hypotension, e.g., resting systolic blood pressure \\\u003C100 mmHg, orthostatic dysregulation etc.\n   * Clinical signs of dyspnea, e.g., speech dyspnea, resting respiratory rate \\>20 breaths\u002Fmin.\n2. Thrombocytopenia with platelets \\\u003C60 x 109 \u002FL\n3. Confirmed bleeding disorder with the need for specific preventive perioperative treatment (e.g., factor deficiency with the need of perioperative substitution)\n4. A priori refusal of blood transfusions\n5. Confirmed thrombophilia with a pertinent need for perioperative anticoagulation\n6. Allergy \u002F hypersensitivity to tranexamic acid\n7. Recent (\\\u003C30 days) thromboembolic event\n8. History of medically confirmed convulsions\n9. In female subjects: pregnancy or lactation","ALL","18 Years",{"count":20,"type":21},850,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to learn if the administration of tranexamic acid can reduce the necessity of blood transfusions in adult patients undergoing major abdominal surgery. . It will also inform about safety of tranexamic acid in this setting.\n\nThe main question it aims to answer is: Does tranexamic acid lower the probability of receiving at least one blood transfusion during or after surgery?\n\nParticipants will compare tranexamic acid o a placebo (a look-alike substance that contains no drug) to see if tranexamic acid works to reduce the necessity of a blood transfusion.",[27,28,29],"Surgical Blood Loss","Transfusion-dependent Anemia","Abdomen Disease","RECRUITING","2026-04-28",{"date":33,"type":34},"2026-04-29","ACTUAL",{"date":36,"type":34},"2024-06-17",{"date":38,"type":21},"2026-11-30",{"name":40,"class":41},"Ulrich Ronellenfitsch, MD","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":42},"100635240","pvi-vs-esp-block-for-reducing-bleeding-and-postoperative-pain-in-lumbar-fusion-surgery-100635240","NCT07550114","PVI vs ESP Block for Reducing Bleeding and Postoperative Pain in Lumbar Fusion Surgery.","EFFICACY OF PERIARTICULAR VASOCONSTRICTOR INFILTRATION (PVI) VERSUS ERECTOR SPINAE PLANE BLOCK (ESP) IN REDUCING BLEEDING AND POSTOPERATIVE PAIN CONTROL IN LUMBAR FUSION SURGERY: RANDOMIZED CLINICAL TRIAL.","Inclusion Criteria:\n\n* More than 18 years old.\n* ASA I-III\n* Scheduled primary spinal instrumentation surgery (lumbar\u002Fthoracolumbar fusion)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Allergy\u002Fcontraindication to study drugs (ropivacaine, epinephrine)\n* Coagulopathy.\n* Infection at block site\n* Neuromuscular disease affecting evaluation.\n* Chronic opioid use (\\>30mg morphine equivalents\u002Fday)\n* Cognitive impairment preventing pain reporting.\n* Pregnancy",{"count":51,"type":21},62,[53],"NA","This randomized controlled trial compares periarticular vasoconstrictor infiltration (PVI) versus erector spinae plane block (ESP) to reduce bleeding and postoperative pain in adults undergoing lumbar fusion surgery (up to 3 levels). Patients are randomly assigned 1:1 to receive ultrasound-guided ropivacaine 0.2% + epinephrine 1:200,000: PVI (150-200mL bilateral in retrolaminar, thoracolumbar fascia, supraspinous ligament, subcutaneous planes) or ESP (20mL\u002Fside at transverse processes). Both groups receive standardized general anesthesia (TIVA), multimodal analgesia (dexamethasone, paracetamol, dexketoprofen\u002Fmetamizole, ketamine, magnesium), and tranexamic acid. Multicenter study: Hospital de la Santa Creu i Sant Pau (Barcelona, 32 patients) and Hospital Quirón Salud Murcia (30 patients). Primary outcome: intraoperative blood loss (surgical aspirate minus irrigation + gravimetric gauze weight). Secondary outcomes: Fromme surgical field scale, pain (NRS at REA discharge\u002F24h\u002F48h), opioid consumption (morphine equivalents), PONV\u002Fantiemetic use, drain output, hospital stay, patient satisfaction. N=62 patients (31\u002Farm). Blinded outcome assessment.",[27,56,57],"Postoperative Pain","Lumbar Spinal Fusion Surgery",[59,60,61,62,63,64,65,66],"Lumbar fusion","ESP block","PVI block","Intraoperative bleeding","Postoperative pain","WALANT","ropivacaine","epinephrine","2026-04-19",{"date":69,"type":34},"2026-04-24",{"date":71,"type":34},"2026-01-08",{"date":73,"type":21},"2028-03-01",{"name":75,"class":41},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100528745","enucleation-of-pancreatic-tumor-by-blocking-abdominal-trunk-and-superior-mesenteric-artery-100528745","NCT06164769","Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery","A Prospective Study of Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery","Inclusion Criteria:\n\n* Benign or borderline tumors diagnosed pathologically, such as pancreatic neuroendocrine tumors, solid pseudopapillary tumors, and cystadenomas, without vascular invasion or distant metastasis\n* Tumors sited in the pancreatic head, neck, and uncinate process of pancreas\n* Blockade of both the abdominal trunk and superior mesenteric artery in the laparoscopic enucleation\n\nExclusion Criteria:\n\n* Highly malignant pancreatic tumors, or tumors with infiltration or metastasis\n* Tumors of the body and tail of the pancreas\n* Transfer to LPD or laparotomy","14 Years","70 Years",{"count":86,"type":21},30,[53],"Pancreatic enucleation could preserve more healthy pancreatic tissues and functions with a low recurrence risk. However, conventional enucleation can cause significant intraoperative bleeding, especially in which tumors in the pancreatic head, neck, and uncinate process of pancreas, as these tissues are rich in blood supply, mainly including the abdominal trunk and the superior mesenteric artery. In this study, we developed a novel method to control the pancreatic blood flow in laparoscopic enucleation--blocking the abdominal trunk and superior mesenteric artery with vascular occlusion clips in the process of resection, and evaluated its effectiveness and safety.",[90,27],"Tumor of Pancreas",[92,93,94,95,96],"Enucleation","pancreatic tumors","blood loss","the abdominal trunk","superior mesenteric artery","2025-05-27",{"date":99,"type":34},"2025-06-02",{"date":101,"type":34},"2023-03-01",{"date":103,"type":21},"2026-06-30",{"name":105,"class":41},"Zhejiang University",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100556136","usability-of-pericardial-flushing-with-the-haermonics-pure-system-after-cardiac-surgery-100556136","NCT06521164","Usability of Pericardial Flushing with the Haermonics Pure System After Cardiac Surgery","USEPURE","Inclusion Criteria:\n\n1. Adult patients (≥18yrs and weight ≥40kg) undergoing cardiothoracic surgery (CABG and\u002For valve surgery, elective aortic surgery, Bentall procedure, ascending aorto\u002Faortic arch replacement) with the use of cardiopulmonary bypass\n2. Patient has been informed of the nature of the clinical investigation and is willing and able to give written informed consent for investigation participation\n\nExclusion Criteria:\n\n1. Euroscore II \\> 20%\n2. Emergent procedures\n3. Complication during surgery which is life threatening and\u002For requires another surgical intervention\n4. Minimal invasive cardiac surgery procedures (e.g. minithoracotomy and hemisternotomy)\n5. Thoraco-abdominal surgery, or intraoperative injury to the diaphragm leading to an open connection between the thoracic and abdominal cavity\n6. Participation in any study involving an investigational drug or device\n7. Patient is pregnant or nursing\n8. Inability to understand study information",{"count":115,"type":21},65,[53],"The goal of this clinical trial is to evaluate the usability of the Haermonics Pure system in patients undergoing a cardiac surgery procedure with the use of cardiopulmonary bypass.\n\nAll measurements and interventions are standard of care, except pericardial flushing with the Haermonics Pure system.",[27,119],"Surgical Complication",[121,122,123,124,125],"cardiac surgery","therapeutic irrigation","postoperative bleeding","chest tubes","Haermonics Pure System","NOT_YET_RECRUITING","2025-03-11",{"date":129,"type":34},"2025-03-14",{"date":131,"type":21},"2025-10-01",{"date":133,"type":21},"2026-05",{"name":135,"class":136},"Haermonics BV","INDUSTRY",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":106},"100563930","phase-3-decreasing-postoperative-blood-loss-and-seizures-by-timing-of-intravenous-tranexamic-acid-2-pilot-trial-100563930","NCT06622564","Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial","Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION)-2 Pilot Trial","DEPOSITION-2","Inclusion Criteria:\n\n1. ≥18 years of age\n2. Undergoing a cardiac surgical procedure (i.e., isolated CABG, isolated single cardiac valve surgery or a combination of both or isolated ascending aorta replacement) with the use of cardiopulmonary bypass\n3. Provide written informed consent\n\nExclusion Criteria:\n\n1. Allergy to tranexamic acid\n2. Fulfill any of the following transfusion risk factors (A-F):\n\n   A. Emergency surgery B. History of bleeding disorder C. Inherited thromboembolic or hemorrhagic disease D. Infective endocarditis (active) E. Pre-operative thrombocytopenia (\\<50,000 platelets per µL) F. Pre-operative hemoglobin \\<110 g\u002FL\n3. Estimated glomerular filtration rate \\<30 mL\u002Fmin (CKD-EPI equation) or on dialysis\n4. Pre-operative hemoglobin \\>170 g\u002FL\n5. Expected circulatory arrest\n6. Pregnancy or breast feeding\n7. Previous enrollment in DEPOSITION trial\n8. Refusal of blood products (e.g., Jehovah's Witnesses)\n9. Isolated Pericardiectomy","100 Years",{"count":147,"type":21},40,[24],"The goal of this clinical trial is to establish the feasibility of conducting a large trial to determine the optimal timing of intravenous tranexamic acid administration in cardiac surgery. The main questions it aims to answer are:\n\n* Is it feasible to conduct a larger definitive trial?\n* Can we measure the systemic tranexamic acid concentration and fibrinolytic potential in the blood samples?\n\nResearchers will compare intravenous tranexamic acid administered before cardiopulmonary bypass versus after cardiopulmonary bypass to see if the systemic tranexamic acid concentration and fibrinolytic potential are similar or better.\n\nParticipants will:\n\n* Provide written informed consent\n* Receive tranexamic acid during surgery\n* Provide blood samples at 5 time points: before surgery, on arrival in intensive care unit, 3 hours after arrival, 6 hours after arrival, and on the next morning.",[151,27,152],"Bleeding","Seizures",[121,154,155,156,157],"tranexamic acid","cardiopulmonary bypass","seizure","blood transfusion","2024-09-30",{"date":160,"type":34},"2024-10-02",{"date":162,"type":21},"2025-01-01",{"date":164,"type":21},"2026-02-01",{"name":166,"class":41},"Hamilton Health Sciences Corporation",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":174,"sex":17,"minAge":4,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100468419","teg-use-in-children-undergoing-procedures-with-high-anticipated-blood-loss-100468419","NCT05379530","TEG Use in Children Undergoing Procedures With High Anticipated Blood Loss","Thromboelastography (TEG) and Intraoperative Coagulation Management of Pediatric Patients Undergoing Procedures With High Anticipated Blood Loss","Inclusion Criteria:\n\n* Pediatric patients undergoing non-cardiac surgery at BCH with a high likelihood of blood transfusion. Specifically these are defined as a surgery with greater than 25% likelihood of transfusion of any non-albumin blood product.\n* Eligible surgeries include:\n* spinal surgery\n* laparotomy\n* liver transplant\n* craniofacial surgery\n* esophageal atresia\n* craniotomy\u002Fhemispherectomy\n* major abdominal surgery\n* major hip surgery\n* major plastic surgery\n\nExclusion Criteria:\n\n* Patients undergoing cardiac surgery or ECMO cannulation, as these surgeries are generally considered outside the scope of general pediatric surgery.\n* Patients presenting for emergent surgery\n* Patients undergoing surgeries off hours (between 8pm and 8 am), when TEG analysis is unobtainable",true,"20 Years",{"count":177,"type":21},60,[53],"The research team proposes a prospective, observational study to better understand how TEG can be useful in guiding clinical practice in the Main OR for subject's undergoing high transfusion risk surgeries.\n\nIntraoperatively, transfusion of blood products is frequently required to restore oxygen carrying capacity, perfusion and improve coagulation. Both under and over transfusion pose significant risks, particularly to pediatric patients with small starting intravascular volumes. Thromboelastography (TEG) is a validated method of dynamically assessing intraoperative coagulopathy via functional assay. However, while FDA approved and widely used in the adult setting, TEG is not commonly utilized in the setting of bleeding pediatric patients.\n\nRecently, TEG has been made available at BCH for clinical purposes and is being used solely in the cardiac surgery setting. The investigators aim to provide TEG data for non-cardiac pediatric surgical cases with a high risk of intraoperative blood loss in order to assess the impact of this tool on intraoperative management.",[27,181,182],"Surgical Hemorrhage","Post Operative Hemorrhage",[184,157,185,186],"thromboelastography","viscoelastic test-guided","massive hemorrhage","2024-08-19",{"date":189,"type":34},"2024-08-20",{"date":162,"type":21},{"date":192,"type":21},"2025-12-01",{"name":194,"class":41},"Boston Children's Hospital"]